title: AngiotensinII preconditioning promotes angiogenesis in vitro via ERKs phosphorylation.
abstract: AngiotensinII (AngII) is involved in not only the formation of cardiac hypertrophy but also the development of cardiac remodeling both of which are associated with myocardial angiogenesis. This study was therefore performed to clarify the effects of AngII on the formation of vasculatures by cultured cardiac microvascular endothelial cells (CMVECs) after a long-period stimulation with or without the AngII preconditioning. Incubation with AngII for 18 hrs significantly impaired the formation of capillary-like tubes comparing to that without AngII. CMVECs with AngII pretreatment for 5 and 10 min formed more capillary-like tubes than those without AngII pretreatment, suggesting that preconditioning with AngII at a lower dose for a short period could prevent the further damage of CMVECs by a higher concentration of AngII. Moreover, AngII (10(-7) M) stimulation for 5 and 10 min significantly induced the increase in extracellular signal-regulated protein kinases (ERKs) phosphorylation, and an ERKs inhibitor, PD98059, abrogated the increase in the formation of capillary-like tubes induced by the AngII-pretreatment. In conclusion, preconditioning with a lower concentration of AngII for a short period prevents the subsequent impairment of CMVECs by a higher dose of AngII, at least in part, through the increase in ERKs phosphorylation.
authors.affiliation: Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Aili
authors.initials: A
authors.lastname: Guan
authors.forename: Yunzeng
authors.initials: Y
authors.lastname: Zou
authors.forename: Hui
authors.initials: H
authors.lastname: Gong
authors.forename: Yuhong
authors.initials: Y
authors.lastname: Niu
authors.forename: Yong
authors.initials: Y
authors.lastname: Ye
authors.forename: Jianguo
authors.initials: J
authors.lastname: Jia
authors.forename: Bingyu
authors.initials: B
authors.lastname: Li
authors.forename: Guoping
authors.initials: G
authors.lastname: Zhang
authors.forename: Sanli
authors.initials: S
authors.lastname: Qian
authors.forename: Junbo
authors.initials: J
authors.lastname: Ge
mesh_terms: D000704:Analysis of Variance; D043925:Angiogenesis Inducing Agents / Q000494:pharmacology; D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D002478:Cells, Cultured; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D005419:Flavonoids / Q000494:pharmacology; D008297:Male; D009206:Myocardium / Q000166:cytology; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D010766:Phosphorylation; D020011:Protective Agents / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
chemical_list: D043925:Angiogenesis Inducing Agents; D005419:Flavonoids; D020011:Protective Agents; D000804:Angiotensin II; D048049:Extracellular Signal-Regulated MAP Kinases; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one